Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785670 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL28543039 | 0.73 | MTNR1A (0.40) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL23657803 | 0.72 | MTNR1A (0.39) | MTNR1AALOX15HSD17B10 | |
| SCHEMBL17194140 | 0.70 | ACHE (0.44) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL27566376 | 0.66 | MTNR1A (0.44) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL2030277 | 0.62 | PLAU (0.45) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL12475851 | 0.62 | GAA (0.47) | MTNR1A | |
| SCHEMBL3825586 | 0.62 | PLAU (0.45) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL9965445 | 0.62 | BRD4 (0.55) | MTNR1AMTNR1BMEN1KMT2AEPHX2 | |
| SCHEMBL2152470 | 0.62 | MTNR1A (0.47) | MTNR1AMTNR1BMEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | MTNR1A 28/4885MTNR1B 35/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.